EHA 2017 | Future advancements in the treatment of PNH
Peter Hillmen
• 22 Jun 2017
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, discusses future advancements in and current trials focused on the treatment of the rare disease, paroxysmal nocturnal hemoglobinuria (PNH), including the development of small molecules and monoclonal antibodies which can be administered in a more convenient manner and may be more effective than currently used treatments, such as eculizumab. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
